Transforming growth factor beta (TGFβ) is a cytokine that is secreted by various cell types, including macrophages, and functions in cell growth, cell differentiation, apoptosis and cellular ...

(“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Learn more about six antisense oligonucleotide companies shaping the future of genetic medicine, just as the market is ...

The Series C financing was led by Frazier Life Sciences with participation from additional new investors that included Vivo ...

Keros Therapeutics, Inc. has recently announced its participation in two upcoming healthcare conferences. The company's Chair ...

Surrozen (SRZN) announced a strategic research collaboration with privately-held TCGFB to discover antibody therapeutics targeting Transforming ...

4 release. TCGFB is paying Surrozen up to $6 million, plus any third-party costs, for antibodies that target transforming growth factor beta (TGF-Beta). Dysfunctional TGF-Beta is a major ...

Endothelial cells are also likely to participate in activation, both by production of cellular fibronectin and via conversion of transforming growth factor (TGF)-beta from the latent to active ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Pipeline Highlights Bicara is developing ficerafusp alfa, a first-in-class, dual-action bifunctional epidermal growth factor receptor (EGFR)/transforming growth factor beta (TGF-β) antibody for ...

For the first time, researchers have discovered that the accumulation of aged and failing cells, called senescent cells, in ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.